Ouro will leverage $120 million in funding to develop novel T cell engagers with potential to reset the immune system in patients with chronic immune-mediated ...
INCHEON, Korea and TEL AVIV, Israel I January 10, 2025 I Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced ...
UTRECHT, The Netherlands and PHILADELPHIA, PA, USA I January 10, 2025 I LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage ...
Targeting toxic oligomers without binding to plaque, designed to reduce the risk of ARIA and potentially deliver enhanced outcomes for patients ...
TYRA appoints urologic oncologist, Erik Goluboff, M.D., as SVP, Clinical Development to lead NMIBC--First patient expected to be dosed in SURF302 in Q2 2025-CARLSBAD, CA, USA I J ...
The primary objective of this initial clinical trial is to evaluate safety and immune responses of three different dose levels and two different vaccination schedules of ARCT-2304 vaccine. Immune ...
NEW YORK, NY. USA I January 10, 2025 I Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating ...
BELTSVILLE, MD, USA I January 10, 2025 I NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback